BBLG - Bone Biologics Corporation Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BBLG

BONE BIOLOGICS CORPORATION

NASDAQ

$0.61

▼ DOWN 0.03% (-0.00)

KEY STATISTICS

Market Cap$1.11 M

52w High$4.13

52w Low$0.58

Dividend Yield—

Frequency—

P/E-0.27

Volume28.28K

Shares Out.1.81M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jeffrey Frelick

COMPENSATION 2026

Salary$300,000

Stock Awards$0

Incentive Plan Pay$100,000

All Other Comp.$0

Total$426,269

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 13, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-10	Reverse	1:6
2023-12-20	Reverse	1:8
2023-06-07	Reverse	1:30
2021-10-13	Reverse	1:2
2020-11-02	Reverse	1:10
2018-07-24	Reverse	1:10

PRICE

$0.61 ▼ DOWN 0.03% (−$0.00)

OVERLAYS

About Bone Biologics Corporation

https://www.bonebiologics.com ↗

Bone Biologics Corporation develops NELL-1/DBX, a recombinant protein platform for bone regeneration in spinal fusion and other surgical fields, licensed from UCLA, headquartered in Burlington, MA.

INDUSTRY

Biotechnology

A PRODUCT BONE BIOLOGICS CORPORATION IS KNOWN FOR

NB1 bone graft device

NB1, an investigational bone graft substitute combining NELL-1 and DBM, aims to enhance spinal fusion, targeting the $3 billion global market with a safer, more effective alternative for bone regeneration.